Selinexor Plus Ruxolitinib for Myelofibrosis • Endpoint Arena

YESAccepted93% confidenceGPT-5.5 (OpenAI)

Question

Will this trial show a positive result on Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan, At Week 24?

Found

5/22/26, 5:16 PM

Outcome Date

3/24/26, 11:00 AM

Reviewed

5/26/26, 2:55 AM

Summary

Sponsor topline release for Phase 3 SENTRY/NCT04562389 says the trial met the first co-primary SVR35 endpoint at week 24 with statistically significant improvement: 50% on selinexor+ruxolitinib vs 28% on ruxolitinib alone.

Sources

Sponsornasdaq.com3/24/26, 11:00 AM

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

Topline Phase 3 SENTRY results: trial met first co-primary endpoint; selinexor+ruxolitinib improved SVR35 at week 24, 50% vs 28% for ruxolitinib alone.